Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast implants

This article was originally published in The Gray Sheet

Executive Summary

FDA posts Mentor and Inamed saline breast implant five-year labeling data on its website. The firms presented the updated data at a July 9 meeting of the agency's General and Plastic Surgery Devices Panel (1"The Gray Sheet" July 15, 2002, p. 3). Inamed showed a re-operation rate of 26% for augmentation patients and 44.5% for reconstruction patients, while Mentor re-operation rates were 20% and 43%, respectively...

You may also be interested in...



FDA, Congress Examine Saline Implant Data; Silicone PMA Expected In 2002

Mentor and Inamed should reconvene focus groups to review patient labeling changes for saline-filled breast implants, FDA's General and Plastic Surgery Devices Panel recommended July 9 at its meeting in Gaithersburg, Maryland

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel